SCIENTIFIC JOURNAL of the Hungarian Society of Cardiology

Role of imaging modalities in diagnosing cardiac amyloidosis

█ Review

DOI: 10.26430/CHUNGARICA.2021.51.1.23

Authors:
Pozsonyi Zoltán1, Peskó Gergely1, Czibor Sándor2, Dohy Zsófia3, Vágó Hajnalka31Semmelweis Egyetem, Belgyógyászati és Hematológiai Klinika, Budapest
2Semmelweis Egyetem, Orvosi Képalkotó Klinika, Nukleáris Medicina Tanszék, Budapest
3Semmelweis Egyetem, Városmajori Szív- és Érgyógyászati Klinika, Budapest

Summary

Role of imaging modalities in diagnosing cardiac amyloidosis
Systemic amyloidosis affecting the heart is recognized more often. It is partially because of the extensive use of sensitive imagining studies. On the other hand, in the last couple of years new pharmacological treatment options were developed for nearly all types of cardiac amyloidosis, which promise significant clinical benefit for the patients. The suspicion of cardiac amyloidosis should arise primarily with left ventricular hypertrophy without clear etiology, with heart failure with preserved ejection fraction, with low-flow-low-grade aortic stenosis and with further clinical signs of the disease.

When systemic amyloidosis is diagnosed then evaluation for heart involvement should be done. To reduce the long diagnostic delay, clinicians and echocardiografists should keep in mind this possible diagnosis. It is important, that cardiac imaging studies have a key role in the diagnosis of cardiac amyloidosis, and should be performed with clear indications. A consensus document was published recently on the role of imaging modalities in cardiac amyloidosis. Our review helps the reader to be up-to-date with the diagnosis of cardiac amyloidosis, and highlights the importance of imaging studies.

 

ISSUE: CARDIOLOGIA HUNGARICA | 2021 | VOLUME 51, ISSUE 1

click here to read the full article

click here to read the pdf